BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18646607)

  • 21. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
    Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
    Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience.
    Chen W; Karandikar NJ; McKenna RW; Kroft SH
    Am J Clin Pathol; 2007 Jan; 127(1):39-46. PubMed ID: 17145625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloid cell-associated lysosomal proteins as flow cytometry markers for leukocyte lineage classification.
    Strobl H; Knapp W
    J Biol Regul Homeost Agents; 2004; 18(3-4):335-9. PubMed ID: 15786701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
    Zwick D; Cooley L; Hetherington M
    Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre.
    Motwani J; Jesson J; Sturch E; Jones S; Eyre L; Short P; Davies P; Williams MD; Darbyshire PJ; Hill FG; Lawson S
    Br J Haematol; 2009 Jan; 144(1):133-5. PubMed ID: 19016737
    [No Abstract]   [Full Text] [Related]  

  • 26. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology.
    Duque RE; Andreeff M; Braylan RC; Diamond LW; Peiper SC
    Cytometry; 1993; 14(5):492-6. PubMed ID: 8354121
    [No Abstract]   [Full Text] [Related]  

  • 27. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group.
    Krejci O; van der Velden VH; Bader P; Kreyenberg H; Goulden N; Hancock J; Schilham MW; Lankester A; Révész T; Klingebiel T; van Dongen JJ
    Bone Marrow Transplant; 2003 Oct; 32(8):849-51. PubMed ID: 14520434
    [No Abstract]   [Full Text] [Related]  

  • 28. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
    Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
    Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
    Owen RG; Rawstron AC
    Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
    [No Abstract]   [Full Text] [Related]  

  • 31. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
    Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy.
    Nowak R; Oelschlägel U; Hofmann R; Zengler H; Huhn R
    Leuk Res; 1994 Dec; 18(12):897-901. PubMed ID: 7527882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Go with the flow for monitoring response in myeloma with minimal residual disease.
    Mason KD; Juneja S
    Leuk Lymphoma; 2008 Feb; 49(2):177-8. PubMed ID: 18231901
    [No Abstract]   [Full Text] [Related]  

  • 34. Infant acute bilineal leukemia.
    Derwich K; Sedek L; Meyer C; Pieczonka A; Dawidowska M; Gaworczyk A; Wachowiak J; Konatkowska B; Witt M; Marschalek R; Szczepański T
    Leuk Res; 2009 Jul; 33(7):1005-8. PubMed ID: 19286255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.
    Böttcher S
    Methods Mol Biol; 2019; 1956():157-197. PubMed ID: 30779035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia].
    Savva NN; Belevtsev MV; Savitskiĭ VP; Migal' NV; Movchan LV; Aleĭnikova OV
    Klin Lab Diagn; 2009 Dec; (12):15-8. PubMed ID: 20140998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of a chemiluminescent methodology for detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Lo Nigro L; Poli A; Mirabile E; Costantino F; Schilirò G
    Haematologica; 2001 Dec; 86(12):1314-6. PubMed ID: 11726326
    [No Abstract]   [Full Text] [Related]  

  • 39. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
    de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
    Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
    [No Abstract]   [Full Text] [Related]  

  • 40. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.